Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Martín Moreno, Ana María ^a,b,g   Brera, Begoña ^a,b   Spuch, Carlos ^b,c,h   Carro, Eva ^b,c   García García, Luis ^d   Delgado, Mercedes ^d   Pozo, Miguel A ^d,e   Innamorato, Nadia G ^b,f   Cuadrado, Antonio ^b,f   de Ceballos, María L ^a,b  

^a INSTITUTO CAJAL   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c Universidad Complutense   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e PET Technology Institute   (Spain)

^f AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^g MD ANDERSON CANCER CENTER   (Spain)

^h UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

Author keywords

Alzheimer's disease; Anti inflammatories; Cannabinoids; Glial activation; Interleukin 6; Tumor necrosis factor ; amyloid peptide

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; AMYLOID BETA PROTEIN; CANNABINOID; CYCLOOXYGENASE 2; DRINKING WATER; FLUORODEOXYGLUCOSE F 18; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; TETRAHYDROCANNABINOL; TUMOR NECROSIS FACTOR ALPHA; 1,1 DIMETHYLBUTYL 1 DEOXY DELTA(9) THC; 1,1-DIMETHYLBUTYL-1-DEOXY-DELTA(9)-THC; AMYLOID PRECURSOR PROTEIN; BENZOXAZINE DERIVATIVE; CANNABINOID 2 RECEPTOR; GLYCOGEN SYNTHASE KINASE 3 BETA; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PTGS2 PROTEIN, MOUSE;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL DENSITY; CEREBELLUM; CHOROID PLEXUS; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; ENCEPHALITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FRONTAL CORTEX; GENOTYPE; GLUCOSE TRANSPORT; HIPPOCAMPUS; IMMUNOREACTIVITY; IN VITRO STUDY; LONG TERM CARE; LOW DRUG DOSE; MICROGLIA; MOUSE; NEUROPROTECTION; NONHUMAN; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; WESTERN BLOTTING; ANALYSIS OF VARIANCE; ANIMAL; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; SCINTISCANNING; TIME; TRANSGENIC MOUSE;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; BENZOXAZINES; CANNABINOIDS; CHOROID PLEXUS; COGNITION DISORDERS; CORPUS STRIATUM; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; ENCEPHALITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; MICE, TRANSGENIC; MICROGLIA; MORPHOLINES; NAPHTHALENES; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, CANNABINOID, CB2; RNA, MESSENGER; TIME FACTORS;

EID: 84855812968     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-8     Document Type: Article

References (72)

1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Giffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21:383-421. 10.1016/S0197-4580(00)00124-X, 10858586.
2. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease -a double-edged sword. Neuron 2002, 35:419-432. 10.1016/S0896-6273(02)00794-8, 12165466.
3. Breitner JC, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, Pericak-Vance MA, Saunders AM. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995, 16:523-530. 10.1016/0197-4580(95)00049-K, 8544901.
4. In 't Veld BA, Launer LJ, Hoes AW, Ott A, Hofman A, Breteler MM, Stricker BH. NSAIDs and incident Alzheimer's disease. The Rotterdam Study. Neurobiol Aging 1998, 19:607-611. 10.1016/S0197-4580(98)00096-7, 10192221.
5. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1997, 47:425-432.
6. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54:161-202. 10.1124/pr.54.2.161, 12037135.
7. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003, 4:873-884. 10.1038/nrn1247, 14595399.
8. Begg M, Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Mo FM, Liu J, Kunos G. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005, 106:133-145. 10.1016/j.pharmthera.2004.11.005, 15866316.
9. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 2010, 58:1017-1030. 10.1002/glia.20983, 2919281, 20468046.
10. Stella N. Cannabinoid signaling in glial cells. Glia 2004, 48:267-277. 10.1002/glia.20084, 15390110.
11. Walter L, Stella N. Cannabinoids and neuroinflammation. Brit J Pharmacol 2004, 141:775-785.
12. Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005, 25:1904-1913. 10.1523/JNEUROSCI.4540-04.2005, 15728830.
13. Benito C, Núñez E, Pazos MR, Tolón RM, Romero J. The endocannabinoid system and Alzheimer's disease. Mol Neurobiol 2007, 36:75-81. 10.1007/s12035-007-8006-8, 17952652.
14. Campbell VA, Gowran A. Alzheimer's disease; taking the edge off with cannabinoids?. Br J Pharmacol 2007, 152:655-662. 2190031, 17828287.
15. Mechoulam R, Spatz M, Shohami E. Endocannabinoids and Neuroprotection. Sci STKE 2002, re5.
16. van der Stelt M, Veldhuis WB, Maccarrone M, Bär PR, Nicolay K, Veldink GA, Di Marzo V, Vliegentahart JFG. Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 2002, 26:317-346. 10.1385/MN:26:2-3:317, 12428763.
17. Correa FG, Mestre L, Docagne F, Borrell J, Guaza C. The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis. Vitam Horm 2009, 81:207-230.
18. Klein WK. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005, 5:400-411. 10.1038/nri1602, 15864274.
19. Cabral GA, Marciano-Cabral F. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J Leukoc Biol 2005, 78:1192-1197. 10.1189/jlb.0405216, 16204639.
20. Martín-Moreno AM, Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A, de Ceballos ML. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharmacol 2011, 79:964-973. 10.1124/mol.111.071290, 21350020.
21. Ehrhart J, Obregon D, Mori T, Hou H, Sun N, Bai Y, Klein T, Fernandez F, Tan J, Shytle RD. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2005, 2:29. 10.1186/1742-2094-2-29, 1352348, 16343349.
22. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 2004, 89:134-141. 10.1111/j.1471-4159.2003.02327.x, 15030397.
23. Esposito G, De Filipis D, Carnuccio R, Izzo AA, Iuvone T. The marijuana component cannabidiol inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue PC12 cells. J Mol Med 2006, 84:253-258. 10.1007/s00109-005-0025-1, 16389547.
24. Esposito G, De Filipis D, Mauiuri MC, De Stefano D, Carnuccio R, Iuvone T. Cannabidiol inhibits nitric oxide synthase protein expression and nitric oxide production in β-amyloid stimulated PC12 neurons through p38 MAP kinase and NFκB involvement. Neurosci Lett 2006, 399:91-95. 10.1016/j.neulet.2006.01.047, 16490313.
25. van der Stelt M, Mazzola C, Esposito G, Matias I, Petrosino S, De Filippis D, Micale V, Steardo L, Drago F, Iuvone T, Di Marzo V. Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci 2006, 63:1410-1424. 10.1007/s00018-006-6037-3, 16732431.
26. Frautschy SA, Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole GM. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 1998, 152:307-317. 1858113, 9422548.
27. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci 1996, 16:5795-5811.
28. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 1997, 56:965-973. 10.1097/00005072-199709000-00002, 9291938.
29. Huffman JW, Liddle J, Yu S, Aung MM, Aboot ME, Wiley JL, Martin BR. 3-(1',1'-Dimethylbutyl)-1-deoxy-delta-8-THC and related compounds: synthesis and selective ligands for the CB2 receptor. Bioorg Med Chem Lett 1999, 7:2905-2914.
30. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer A, Frossard JL, Mach F. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005, 434:782-786. 10.1038/nature03389, 15815632.
31. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005, 32:486-510. 10.1007/s00259-005-1762-7, 15747152.
32. Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, Sagredo O, Benito C, Romero J, Azcoitia I, Fernández-Ruiz J, Guzmán M, Galve-Roperh I. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009, 132:3152-3164. 10.1093/brain/awp239, 19805493.
33. Halleskog C, Mulder J, Dahlström J, Mackie K, Hortobágyi T, Tanila H, Kumar Puli L, Färber K, Harkany T, Schulte G. WNT signaling in activated microglia is proinflammatory. Glia 2011, 59:119-131. 10.1002/glia.21081, 3064522, 20967887.
34. Ashton JC, Appleton I, Darlington CL, Smith PF. Cannabinoid CB1 receptor protein expression in the rat choroid plexus: a possible involvement of cannabinoids in the regulation of cerebrospinal fluid. Neurosci Lett 2004, 364:40-42. 10.1016/j.neulet.2004.04.016, 15193752.
35. Suárez J, Romero-Zerbo SY, Rivera P, Bermúdez-Silva FJ, Pérez J, De Fonseca FR, Fernández-Llebrez P. Endocannabinoid system in the adult rat circumventricular areas: an immunohistochemical study. J Comp Neurol 2010, 518:3065-3085. 10.1002/cne.22382, 20533360.
36. Chen B, Bromley-Brits K, He G, Cai F, Zhang X, Song W. Effect of synthetic cannabinoid HU210 on memory deficits and neuropathology in Alzheimer's disease mouse model. Curr Alzheimer Res 2010, 7:255-261. 10.2174/156720510791050948, 20043809.
37. Baek J, Zheng Y, Darlington CL, Smith PF. The CB1 receptor agonist, WIN 55,212-2, dose-dependently disrupts object recognition memory in adult rats. Neurosci Lett 2009, 464:71-73. 10.1016/j.neulet.2009.08.008, 19666083.
38. Lichtman AH, Varvel SA, Martin BR. Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fatty Acids 2002, 66:269-285. 10.1054/plef.2001.0351, 12052042.
39. Yim TT, Hong NS, Ejaredar M, McKenna JE, McDonald RJ. Post-training CB1 cannabinoid receptor agonist activation disrupts long-term consolidation of spatial memories in the hippocampus. Neuroscience 2008, 151:929-936. 10.1016/j.neuroscience.2007.08.037, 18248907.
40. Abood ME, Martin BR. Molecular neurobiology of the cannabinoid receptor. Int Rev Neurobiol 1996, 39:197-221.
41. Hampson RE, Simeral JD, Kelly EJ, Deadwyler SA. Tolerance to the memory disruptive effects of cannabinoids involves adaptation by hippocampal neurons. Hippocampus 2003, 13:543-556. 10.1002/hipo.10081, 12921345.
42. Sánchez C, de Ceballos ML, Gómez del Pulgar T, Rueda D, Corbacho C, Velasco G, Galve-Roperh I, Huffman JW, Ramón y Cajal S, Guzmán M. Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Res 2001, 61:5784-5789.
43. Clarke JR, Rossato JI, Monteiro S, Bevilaqua LR, Izquierdo I, Cammarota M. Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem 2008, 90:374-381. 10.1016/j.nlm.2008.04.009, 18524639.
44. Berti V, Osorio RS, Mosconi L, Li Y, De Santi S, de Leon MJ. Early detection of Alzheimer's disease with PET imaging. Neurodegener Dis 2010, 7:131-135. 10.1159/000289222, 3214828, 20197691.
45. Pontieri FE, Conti G, Zocchi A, Fieschi C, Orzi F. Metabolic mapping of the effects of WIN 55212-2 intravenous administration in the rat. Neuropsycho-pharmacology 1999, 21:773-776.
46. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis 2002, 9:61-68. 10.1006/nbdi.2001.0460, 11848685.
47. Sadowski M, Pankiewicz J, Scholtzova H, Ji Y, Quartermain D, Jensen CH, Duff K, Nixon RA, Gruen RJ, Wisniewski T. Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice. J Neuropathol Exp Neurol 2004, 63:418-428.
48. Chapman TR, Barrientos RM, Ahrendsen JT, Maier SF, Patterson SL. Synaptic correlates of increased cognitive vulnerability with aging: peripheral immune challenge and aging interact to disrupt theta-burst late-phase long-term potentiation in hippocampal area CA1. J Neurosci 2010, 30:7598-7603. 10.1523/JNEUROSCI.5172-09.2010, 2891807, 20519534.
49. Marchalant Y, Brothers HM, Norman GJ, Karelina K, DeVries AC, Wenk GL. Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis. Neurobiol Dis 2009, 34:300-307. 10.1016/j.nbd.2009.01.014, 19385063.
50. Marchalant Y, Cerbai F, Brothers HM, Wenk GL. Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats. Neurobiol Aging 2008, 29:1894-1901. 10.1016/j.neurobiolaging.2007.04.028, 2586121, 17561311.
51. Esposito G, Scuderi C, Savani C, Steardo L, De Filippis D, Cottone P, Iuvone T, Cuomo V, Steardo L. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol 2007, 151:1272-1279. 2189818, 17592514.
52. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102. 10.1126/science.274.5284.99, 8810256.
53. Mehlhorn G, Hollborn M, Schliebs R. Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int J Dev Neurosci 2000, 18:423-431. 10.1016/S0736-5748(00)00012-5, 10817926.
54. Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammation 2006, 3:27. 10.1186/1742-2094-3-27, 1609108, 17005052.
55. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 2005, 128:1442-1453. 10.1093/brain/awh452, 15817521.
56. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, Patel KD, Sharkey KA. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310:329-332. 10.1126/science.1115740, 16224028.
57. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6:916-919. 10.1038/78682, 10932230.
58. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177. 10.1038/22124, 10408445.
59. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-β levels. Nat Med 2002, 8:1390-1397. 10.1038/nm1202-793, 12415260.
60. Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 2003, 23:29-33.
61. Molina-Holgado E, Vela JM, Arévalo-Martín A, Almazán G, Molina-Holgado F, Borrell J, Guaza C. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 2002, 22:9742-9753.
62. Ozaita A, Puighermanal E, Maldonado R. Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J Neurochem 2007, 102:1105-1114. 10.1111/j.1471-4159.2007.04642.x, 17484726.
63. Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little?. Neuron 2009, 64:110-122. 10.1016/j.neuron.2009.08.039, 2834890, 19840553.
64. Gómez-Isla T, Blesa R, Boada M, Clarimón J, Del Ser T, Domenech G, Ferro JM, Gómez-Ansón B, Manubens JM, Martínez-Lage JM, Muñoz D, Peña-Casanova J, Torres F, . TRIMCI Study Group A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis Assoc Disord 2008, 22:21-29. 10.1097/WAD.0b013e3181611024, 18317243, TRIMCI Study Group.
65. Coma M, Serenó L, Da Rocha-Souto B, Scotton TC, España J, Sánchez MB, Rodríguez M, Agulló J, Guardia-Laguarta C, Garcia-Alloza M, Borrelli LA, Clarimón J, Lleó A, Bacskai BJ, Saura CA, Hyman BT, Gómez-Isla T. Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease. Neurobiology of Disease 2010, 38:482-491. 10.1016/j.nbd.2010.01.019, 20149872.
66. Mulder J, Zilberter M, Pasquaré SJ, Alpár A, Schulte G, Ferreira SG, Köfalvi A, Martín-Moreno AM, Keimpema E, Tanila H, Watanabe M, Mackie K, Hortobágyi T, de Ceballos ML, Harkany T. Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain 2011, 134:1041-1060. 10.1093/brain/awr046, 21459826.
67. Jung KM, Astarita G, Yasar S, Vasilevko V, Cribbs DH, Head E, Cotman CW, Piomelli D. An amyloid β(42)-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease. Neurobiol Aging 2011,
68. Grünblatt E, Zander N, Bartl J, Jie L, Monoranu CM, Arzberger T, Ravid R, Roggendorf W, Gerlach M, Riederer P. Comparison analysis of gene expression patterns between sporadic Alzheimer's and Parkinson's disease. J Alzheimers Dis 2007, 12:291-311.
69. Grünblatt E, Bartl J, Zehetmayer S, Ringel TM, Bauer P, Riederer P, Jacob CP. Gene expression as peripheral biomarkers for sporadic Alzheimer's disease. J Alzheimers Dis 2009, 16:627-634.
70. Horti AG, Gao Y, Ravert HT, Finley P, Valentine H, Wong DF, Endres CJ, Savonenko AV, Dannals RF. Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). Bioorg Med Chem 2010, 18:5202-5207. 10.1016/j.bmc.2010.05.058, 2903661, 20554448.
71. Balcerzyk M, Kontaxakis G, Delgado M, Garcia-Garcia L, Correcher C, Gonzalez AJ, Gonzalez A, Rubio JL, Benlloch JM, Pozo MA. Initial performance evaluation of a high resolution Albira small animal positron emission tomography scanner with monolithic crystals and depth-of-interaction encoding from a user's perspective. Meas Sci Technol 2009, 20104011.
72. Jupp B, O'Brien TJ. Application of coregistration for imaging of animal models of epilepsy. Epilepsia 2007, 48(Suppl 4):82-89.